• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-APOE antibody :: Goat Apolipoprotein E (Apo E) Polyclonal Antibody

Scan QR to view Datasheet
Catalog # MBS315584
Unit / Price
  0.5 mL  /  $475 +1 FREE 8GB USB
anti-APOE antibody
Product Name

Apolipoprotein E (Apo E) (APOE), Polyclonal Antibody

Also Known As

Goat anti Apolipoprotein E

Product Synonym Names
Goat Antibody to Human Apolipoprotein E (Apo E)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Chromosome Location
Chromosome: 19; NC_000019.9 (45409039..45412650). Location: 19q13.2
3D Structure
ModBase 3D Structure for P02649
Apolipoprotein E (Apo E)
Binds to human Apo E.
Human Apo E-Sepharose affinity column, and conjugated with HRP
HRP, Lyophilized
Reconstitute to 0.5ml with distilled water. Centrifuge product if not completely clear after standing for 1-2 hours at room temperature.
1mg/ml (prior to lyophilization) (lot specific)
Purified human Apo E from human plasma
Lyophilized from 50mM PBS, 0.1M Sodium chloride, pH 7.4 containing 10mg/ml BSA
0.01% Thimerosal
Important Note
Centrifuge before opening to ensure complete recovery of vial contents.
Use of sodium azide as a preservative will substantially inhibit the enzyme activity of horseradish peroxidase.
Preparation and Storage
Store lyophilized product at 2 to 8 degree C. After reconstitution, product is stable for several weeks at 2 to 8 degree C as an undiluted liquid. Prepare working dilution only prior to immediate use. For extended storage after reconstitution, we suggest
ISO Certification
Manufactured in an ISO 9001:2008 Certified Laboratory.
Other Notes
Small volumes of anti-APOE antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-APOE antibody
EIA/ELISA, Western Blot
Application Notes for anti-APOE antibody
Can be used for immunoblot (1:100-1:2,000) and ELISA (1:2,000-1:8,000). Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily
NCBI/Uniprot data below describe general gene information for APOE. It may not necessarily be applicable to this product.
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
36,154 Da[Similar Products]
NCBI Official Full Name
Apolipoprotein E
NCBI Official Synonym Full Names
apolipoprotein E
NCBI Official Symbol
NCBI Official Synonym Symbols
  [Similar Products]
NCBI Protein Information
apolipoprotein E; apo-E; apolipoprotein E3; OTTHUMP00000159143; OTTHUMP00000197075; OTTHUMP00000197076; OTTHUMP00000197077
UniProt Protein Name
Apolipoprotein E
Protein Family
UniProt Gene Name
UniProt Entry Name
NCBI Summary for APOE
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq]
UniProt Comments for APOE
Function: Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.

Subcellular location: Secreted.

Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle. Ref.18

Post-translational modification: Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308. Ref.19Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).Phosphorylation sites are present in the extracelllular medium.

Polymorphism: Three common APOE alleles have been identified: APOE*2, APOE*3, and APOE*4. The corresponding three major isoforms, E2, E3, and E4, are recognized according to their relative position after isoelectric focusing. Different mutations causing the same migration pattern after isoelectric focusing define different isoform subtypes. The most common isoform is E3 and is present in 40-90% of the population. Common APOE variants influence lipoprotein metabolism in healthy individuals.

Involvement in disease: Defects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [

MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. Ref.16 Ref.26 Ref.27 Ref.29Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [

MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. Ref.16Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [

MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses. Ref.16 Ref.33 Ref.36Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [

MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians. Ref.16 Ref.30 Ref.32 Ref.37

Sequence similarities: Belongs to the apolipoprotein A1/A4/E family.
Product References and Citations for anti-APOE antibody
• Wassef, H., et al., (2004), "Synthesis and Secretion of ApoC-I and ApoE during Maturation of Human SW872 Liposarcoma Cells", J. Nutr., 134: 2935-2941
• DeMattos, R.B., et al., (1999), "A Test of the Cytosolic Apolipoprotein E Hypo

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated withanti-APOE antibody
 Reference Product  PubMed Publications
 APP antibody  >388 publications with APOE and APP
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.